Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease

Curr Neurol Neurosci Rep. 2010 Jan;10(1):4-6. doi: 10.1007/s11910-009-0082-x.

Author

Harold P Adams Jr¹

Affiliation

¹ Division of Cerebrovascular Diseases, Department of Neurology, University of Iowa Stroke Center, University of Iowa, 200 Hawkings Drive, Iowa City, IA, 52242, USA. harold-adams@uiowa.edu

PMID: 20425218
DOI: 10.1007/s11910-009-0082-x

No abstract available

Publication types

Multicenter Study
Randomized Controlled Trial

MeSH terms

Adenosine / analogs & derivatives*
Adenosine / therapeutic use
Clopidogrel
Coronary Artery Disease / complications*
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Ischemia / etiology*
Ischemia / prevention & control*
Male
Platelet Aggregation Inhibitors / therapeutic use*
Proportional Hazards Models
Ticagrelor
Ticlopidine / analogs & derivatives
Ticlopidine / therapeutic use
Time Factors
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Ticagrelor
Adenosine
Ticlopidine